Agios Pharmaceuticals

Agios, changing its identity, to sell cancer drug business to Servier
Agios, changing its identity, to sell cancer drug business to Servier
BioPharma Dive
Agios Pharmaceuticals
cancer
M&A
Servier
Flag link:
Agios' anemia drug hits goal in phase 3, teeing up 2021 filing
Agios' anemia drug hits goal in phase 3, teeing up 2021 filing
Fierce Biotech
Agios Pharmaceuticals
mitapivat
anemia
PK deficiency
Flag link:
Agios helps identify genes that allow cancer to escape the immune system
Agios helps identify genes that allow cancer to escape the immune system
Fierce Biotech
CRISPR
cancer
Agios Pharmaceuticals
immuno-oncology
Flag link:
Agios up as FDA gives Thermo Fisher glioma test breakthrough status
Agios up as FDA gives Thermo Fisher glioma test breakthrough status
Pharmaforum
Agios Pharmaceuticals
FDA
vorasidenib
brain cancer
glioma
Flag link:
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
Fierce Pharma
drug pricing
Amryt Pharma
Myalept
Agios Pharmaceuticals
Tibsovo
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
BioSpace
Agios Pharmaceuticals
Tibsovo
ivosidenib
clinical trials
cholangiocarcinoma
Flag link:
Agios blood cancer drug lead jumps ship to Aprea Therapeutics
Agios blood cancer drug lead jumps ship to Aprea Therapeutics
Fierce Biotech
Aprea
Agios Pharmaceuticals
Flag link:
Smaller groups await Bristol-Myers Squelgene fallout
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
Could These Be the Next 2 Biotech Buyouts?
Could These Be the Next 2 Biotech Buyouts?
Motley Fool
biotech
M&A
Agios Pharmaceuticals
Clovis Oncology
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
Agios Pharma names a new CEO, one with commercial chops in biotech
Agios Pharma names a new CEO, one with commercial chops in biotech
Stat
Pharma CEOs
Jackie Fouse
Agios Pharmaceuticals
Flag link:
Agios scores its second new drug approval, ivosidenib heads to the AML market
Agios scores its second new drug approval, ivosidenib heads to the AML market
Endpoints
Agios Pharmaceuticals
ivosidenib (AG-120)
AML
acute myeloid leukemia
Flag link:
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Celgene on biotech hunt with Agios, Jounce in crosshairs: FT
Fierce Biotech
Celgene
M&A
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission
Endpoints
Agios Pharmaceuticals
ASH
FDA
IDH1
ivosidenib
Flag link:
Agios Pharma shares dive after anemia treatment development halted
Agios Pharma shares dive after anemia treatment development halted
Marketwatch
Agios Pharmaceuticals
clinical trials
AG-519
pyruvate kinase deficiency
Flag link:
3 Drugs Heading to the FDA Soon
3 Drugs Heading to the FDA Soon
Motley Fool
FDA
Kite Pharma
KTE-C19
Flexion
Zilretta
AG-221
Agios Pharmaceuticals
Celgene
Flag link:
5 Major Clinical Trial Results Coming Up
5 Major Clinical Trial Results Coming Up
24/7 Wall St
clinical trials
Vertex Pharmaceuticals
Orkambi
Puma Biotechnology
neratinib
GW Pharma
Epidiolex
Agios Pharmaceuticals
AG-348
AG-519
Dermira
DRM-04
Flag link:
Celgene expands partnership with Agios into immuno-oncology
Celgene expands partnership with Agios into immuno-oncology
BioPharma Dive
Celgene
Agios Pharmaceuticals
immuno-oncology
AG-120
Flag link:

Pages